孟鲁司特联合沙美特罗替卡松治疗轻中度支气管哮喘的临床观察
[摘要] 目的 观察孟鲁司特联合吸入沙美特罗替卡松(舒利迭)治疗轻中度支气管哮喘的临床疗效及安全性。 方法 66例支气管哮喘患者随机分为实验组35例和对照组31例。实验组口服孟鲁司特10 mg，每晚1次顿服，沙美特罗替卡松每日2次吸入；对照组吸入沙美特罗替卡松，每日2次。观察两组患者哮喘临床症状及肺功能改善情况，记录药物不良反应。 结果 实验组总有效率为91.4%(32/35)，对照组总有效率为83.9%(26/31)，两组间比较差异有统计学意义(P < 0.05)；实验组与对照组治疗前后临床症状及肺功能指标有明显改善，ACT评分显著提高，两组对比差异有统计学意义(P < 0.05)；实验组治疗后临床症状缓解及消失时间均短于对照组，差异有统计学意义(P < 0.05)。两组患者在治疗期间均无严重不良反应。 结论 孟鲁司特联合沙美特罗替卡松治疗轻中度哮喘的疗效优于单独使用沙美特罗替卡松，联合使用能更迅速地改善患者肺功能和临床症状，是安全有效的治疗方案。
[关键词] 支气管哮喘；孟鲁司特；沙美特罗替卡松；肺功能
, 百拇医药
[中图分类号] R562.2+5 [文献标识码] A [文章编号] 1674-4721(2012)07(c)-0057-02
Clinical observation of montelukast combined with seretide in treatment of mild and moderate degree bronchial asthma
GU Ying LU Huiyu GAO Xiaoyan LIN Wen
Department of Respiratory Medicine, Taizhou People's Hospital in Jiangsu Province, Taizhou 225300, China
[Abstract] Objective To observe the clinical efficacy and safety of montelukast combined with seretide (salmeteyol and fluticas) in treatment of mild and moderate degree bronchial asthma. Methods Sixty six patients with mild or moderate degree bronchial asthma were divided into two groups randomly. The experiment group (n = 35) were given montelukast 10 mg/d and seretide accuhaler twice a day. The control group (n = 31) were given seretide accuhaler twice a day. The improvement of the clinical symptoms, the change of lung function and the adverse drug reaction in two groups were observed. Results The total effective rate in experiment group was 91.4%(32/35), in control group was 83.9%(26/31). There was statistical difference between them(P < 0.05). In the follow-up period, the clinical symptoms and lung function significantly improved, the symptom score(ACT) in the experiment group was significantly higher than that in the control group. There were statistical differences between two groups(P < 0.05). The time of clinical symptoms remission in experiment group was shorter than that of the control group，there was statistical difference between them(P < 0.05). No severe adverse events occurred in two groups. Conclusion The clinical symptoms and lung function improvement appears more rapidly in treatment by montelukast combined with seretide than by seretide only. Montelukast combined with seretide is effective and safe in the treatment of asthma.
[Key words] Asthma; Montelukast; Salmeterol and fluticas; Lung function
支气管哮喘是多种炎症细胞参与的慢性呼吸道炎症性疾病，由于气道炎症和气道高反应性，引起反复发作性咳喘、胸闷、气急等症状，导致患者的肺功能及生活质量下降。白三烯受体拮抗剂、糖皮质激素和β2-受体激动剂分别以不同的作用机制有效地缓解哮喘症状、减少发作、改善肺功能[1]。本研究观察孟鲁司特(白三烯受体拮抗剂)联合舒利迭(沙美特罗50 μg+丙酸氟替卡松250 μg)治疗66例轻中度支气管哮喘的临床疗效和安全性，现总结如下：, 百拇医药(顾颖 卢慧宇 高晓燕 林雯)
[关键词] 支气管哮喘；孟鲁司特；沙美特罗替卡松；肺功能
, 百拇医药
[中图分类号] R562.2+5 [文献标识码] A [文章编号] 1674-4721(2012)07(c)-0057-02
Clinical observation of montelukast combined with seretide in treatment of mild and moderate degree bronchial asthma
GU Ying LU Huiyu GAO Xiaoyan LIN Wen
Department of Respiratory Medicine, Taizhou People's Hospital in Jiangsu Province, Taizhou 225300, China
[Abstract] Objective To observe the clinical efficacy and safety of montelukast combined with seretide (salmeteyol and fluticas) in treatment of mild and moderate degree bronchial asthma. Methods Sixty six patients with mild or moderate degree bronchial asthma were divided into two groups randomly. The experiment group (n = 35) were given montelukast 10 mg/d and seretide accuhaler twice a day. The control group (n = 31) were given seretide accuhaler twice a day. The improvement of the clinical symptoms, the change of lung function and the adverse drug reaction in two groups were observed. Results The total effective rate in experiment group was 91.4%(32/35), in control group was 83.9%(26/31). There was statistical difference between them(P < 0.05). In the follow-up period, the clinical symptoms and lung function significantly improved, the symptom score(ACT) in the experiment group was significantly higher than that in the control group. There were statistical differences between two groups(P < 0.05). The time of clinical symptoms remission in experiment group was shorter than that of the control group，there was statistical difference between them(P < 0.05). No severe adverse events occurred in two groups. Conclusion The clinical symptoms and lung function improvement appears more rapidly in treatment by montelukast combined with seretide than by seretide only. Montelukast combined with seretide is effective and safe in the treatment of asthma.
[Key words] Asthma; Montelukast; Salmeterol and fluticas; Lung function
支气管哮喘是多种炎症细胞参与的慢性呼吸道炎症性疾病，由于气道炎症和气道高反应性，引起反复发作性咳喘、胸闷、气急等症状，导致患者的肺功能及生活质量下降。白三烯受体拮抗剂、糖皮质激素和β2-受体激动剂分别以不同的作用机制有效地缓解哮喘症状、减少发作、改善肺功能[1]。本研究观察孟鲁司特(白三烯受体拮抗剂)联合舒利迭(沙美特罗50 μg+丙酸氟替卡松250 μg)治疗66例轻中度支气管哮喘的临床疗效和安全性，现总结如下：, 百拇医药(顾颖 卢慧宇 高晓燕 林雯)